Compositions and methods for treating a disease are described herein. Compositions having plant preparations, microRNAs, and one or more rate limiters are administered to a patient to promote DNA damage repair and modulate endothelial and mitochondrial function, thereby allowing for healing to occur.

Compositions and methods for treating a disease are described herein. Compositions having plant preparations, microRNAs, and one or more rate limiters are administered to a patient to promote DNA damage repair and modulate endothelial and mitochondrial function, thereby allowing for healing to occur.

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.